Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting.Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
Results from a new study show that combining the targeted therapy ramucirumab (Cyramza) with standard chemotherapy lengthens the lives of patients with non-small cell lung cancer (NSCLC). Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A new model predicts that nationwide lung cancer screening for people enrolled in Medicare who have a high risk of the disease would double the percentage of early-stage lung cancers diagnosed over five years. In March 2014, the U.S Preventive Services Task Force (USPSTF) recommended that people age 55 to 80 with a high risk of lung cancer due to cigarette smoking receive screening for the disease each year with low dose computed tomography (CT).
In a recent phase I clinical trial, about 50% of patients receiving a new targeted therapy for worsening non-small cell lung cancer (NSCLC) had the cancer shrink. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, this new targeted therapy, AZD9291, targets changes or mutations to the epidermal growth factor receptor (EGFR).
The combination of docetaxel (Docefrez, Taxotere) and a new drug called ganetespib lengthens patients’ lives when used as a second-line therapy for advanced lung cancer, according to a new, large study. Second-line therapy is treatment that is given after the first treatment stops working.
A new type of targeted immunotherapy (called MPDL3280A) was able to shrink several different types of cancer, including lung, melanoma, kidney, colorectal, and stomach cancers in patients whose cancer had worsened while receiving other treatments. Immunotherapy is designed to boost the body’s natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Specifically, this new treatment targets PD-L1, a protein on the surface of tumor cells that prevents the immune system from fighting the tumor. Basically, this treatment stops PD-L1 from working, which then allows the body’s immune system to fight the cancer.
In a large, 20-year study, researchers found that men with a high level of fitness at middle age have a lower risk of developing and dying from lung and colorectal cancers. They also found that better fitness lowers the risk of dying of prostate cancer.
Patients with stage III non-small cell lung cancer (NSCLC) who participated in a recent study lived longer and had fewer side effects when they received the standard dose of radiation therapy and not the high-dose radiation therapy. Stage III NSCLC is usually difficult or impossible to remove with surgery. Radiation therapy is used to slow the growth and spread of the cancer to lengthen patients’ lives. The standard dose for radiation therapy is 60 Gray (Gy), a measurement of how much radiation is absorbed by the body, although many doctors use higher doses in the hope of better controlling the cancer’s growth.
In a recent international study, researchers found that the targeted therapy drug afatinib kept advanced non-small cell lung cancer (NSCLC) with mutations (changes) to the epidermal growth factor receptor (EGFR) from worsening longer than the standard treatment. Targeted therapy is a treatment that targets a cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, afatinib targets EGFR. In a healthy cell, EGFR allows cells to grow and divide. When there are too many receptors caused by a mutation, as happens in cancer, the cancer cells continue to grow and divide uncontrollably.
A study in Germany showed that it is possible for local community hospitals to test non-small cell lung cancer (NSCLC) for molecular factors involved in the cancer. This means that a greater number of patients will have access to these tests. These molecular factors can be genes, proteins, or features of the tissue environment that contribute to cancer growth and survival. The results of tests for molecular factors often determine whether targeted therapy is a treatment option. Targeted therapy is a treatment that targets the molecular factors involved in cancer growth.
A new immunotherapy (called BMS-936558) helped shrink melanoma, kidney cancer, and non-small cell lung cancer (NSCLC) in a recent early study. Immunotherapy is designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function.